RG7155 (Emactuzumab) is a humanized monoclonal antibody that blocks CSF-1R activation and shows efficacy in mouse tumor models of colon cancer and fibrosarcoma, and a phase 1 clinical trial showed a partial response with emactuzumab in five of seven patients with diffuse-type tenosynovial giant cell tumors (162, 163). The gene discussed is CSF1R; the disease is neoplasm.